Andreas Halvorsen's BMRN Position Overview
Andreas Halvorsen (via Viking Global Investors Lp) currently holds 8.3M shares of BioMarin Pharmaceutical Inc. (BMRN) worth $450.73 M, representing 1.17% of the portfolio. First purchased in 2016-Q1, this long-term strategic position has been held for 39 quarters.
Based on 13F filings, Andreas Halvorsen has maintained a strategic position in BMRN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 2.7M shares. Largest reduction occurred in Q3 2025, reducing 4.0M shares.
Analysis based on 13F filings available since 2013 Q2
Andreas Halvorsen's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Andreas Halvorsen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2016 | +602,116 | New Buy | 602,116 | $82.48 |
| Q2 2016 | -602,116 | Sold Out | 602,116 | $0.00 |
| Q3 2016 | +490,304 | New Buy | 490,304 | $92.52 |
| Q4 2016 | +908,153 | Add 185.22% | 1.4 M | $82.84 |
| Q1 2017 | -522,344 | Reduce 37.35% | 876,113 | $87.78 |
| Q2 2017 | -616,457 | Reduce 70.36% | 259,656 | $90.82 |
| Q3 2017 | -259,656 | Sold Out | 259,656 | $0.00 |
| Q1 2018 | +1.68 M | New Buy | 1.68 M | $81.07 |
| Q2 2018 | +1.58 M | Add 93.75% | 3.26 M | $94.20 |
| Q3 2018 | +869,184 | Add 26.66% | 4.13 M | $96.97 |
| Q4 2018 | +962,696 | Add 23.32% | 5.09 M | $85.15 |
| Q1 2019 | +37,272 | Add 0.73% | 5.13 M | $88.83 |
| Q2 2019 | -2.54 M | Reduce 49.50% | 2.59 M | $85.65 |
| Q3 2019 | +467,753 | Add 18.06% | 3.06 M | $67.40 |
| Q4 2019 | -1.44 M | Reduce 46.97% | 1.62 M | $84.55 |
| Q1 2020 | -168,114 | Reduce 10.37% | 1.45 M | $84.50 |
| Q2 2020 | -1.45 M | Sold Out | 1.45 M | $0.00 |
| Q4 2021 | +2.87 M | New Buy | 2.87 M | $88.35 |
| Q1 2022 | +882,446 | Add 30.75% | 3.75 M | $77.10 |
| Q2 2022 | +1.3 M | Add 34.65% | 5.05 M | $82.87 |
| Q3 2022 | +46,571 | Add 0.92% | 5.1 M | $84.77 |
| Q4 2022 | +174,456 | Add 3.42% | 5.27 M | $103.49 |
| Q1 2023 | -3.11 M | Reduce 58.88% | 2.17 M | $97.24 |
| Q2 2023 | +1.99 M | Add 91.68% | 4.16 M | $86.68 |
| Q3 2023 | +58,671 | Add 1.41% | 4.22 M | $88.48 |
| Q4 2023 | +673,998 | Add 15.99% | 4.89 M | $96.42 |
| Q1 2024 | +1.53 M | Add 31.23% | 6.42 M | $87.34 |
| Q2 2024 | +647,276 | Add 10.09% | 7.06 M | $82.33 |
| Q3 2024 | +2.69 M | Add 38.08% | 9.75 M | $70.29 |
| Q4 2024 | +757,257 | Add 7.76% | 10.51 M | $65.73 |
| Q1 2025 | +289,509 | Add 2.75% | 10.8 M | $70.69 |
| Q2 2025 | +1.49 M | Add 13.78% | 12.29 M | $54.97 |
| Q3 2025 | -3.97 M | Reduce 32.28% | 8.32 M | $54.16 |
Andreas Halvorsen's BioMarin Pharmaceutical Investment FAQs
Andreas Halvorsen first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q1 2016, acquiring 602,116 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen has held BioMarin Pharmaceutical Inc. (BMRN) for 39 quarters since Q1 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q4 2021, adding 2,869,947 shares worth $253.56 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Andreas Halvorsen's firm, Viking Global Investors Lp, owns 8,322,179 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $450.73 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 1.17% of Andreas Halvorsen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 12,288,611 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.